Liraglutide
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
Novo Nordisk · Phase 2 · Completed · Enrollment 706
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| NNC0174-0833, 4.5 mg | n/r | n/r | n/r | n/r | n/r |
| NNC0174-0833, 2.4 mg | n/r | n/r | n/r | n/r | n/r |
| NNC0174-0833, 1.2 mg | n/r | n/r | n/r | n/r | n/r |
| NNC0174-0833, 0.6 mg | n/r | n/r | n/r | n/r | n/r |
| NNC0174-0833 0.3 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo 2.4 mg (NNC0174-0833) | 32 participants | 9 participants | 18 participants | n/r | 0 |
| Placebo 4.5 mg (NNC0174-0833) | 47 participants | 8 participants | 7 participants | n/r | 0 |
| Placebo 1.2 mg (NNC0174-0833) | 37 participants | 5 participants | 8 participants | n/r | 0 |
| Placebo 0.6 mg (NNC0174-0833) | 27 participants | 6 participants | 10 participants | n/r | 0 |
| Placebo 0.3 mg (NNC0174-0833) | 20 participants | 6 participants | 15 participants | n/r | 0 |
| Liraglutide 3.0 mg | n/r | n/r | n/r | n/r | n/r |
| Placebo 3.0 mg (Liraglutide) | 39 participants | 20 participants | 18 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.